Report: Celtics Still Considering Two More Offseason Trades
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Brad Stevens and the Boston Celtics have been busy this offseason. Due to the torn Achilles injury suffered by Jayson Tatum and the team's luxury tax situation, the Celtics were forced to trade away two of their main pieces early on in the offseason.
First, the team made a big trade with the Portland Trail Blazers to ship out veteran star guard Jrue Holiday. Boston received Anfernee Simons in return as the centerpiece of the deal.
After that move, the Celtics made a trade to send Kristaps Porzingis to the Atlanta Hawks. Georges Niang was the main piece received back in that trade.
Head coach Brad Stevens of the Boston Celtics looks on against the Brooklyn Nets in Game One of the First Round of the 2021 NBA Playoffs at Barclays Center at Barclays Center on May 22,...
Head coach Brad Stevens of the Boston Celtics looks on against the Brooklyn Nets in Game One of the First Round of the 2021 NBA Playoffs at Barclays Center at Barclays Center on May 22, 2021 in New York City. More
Photo byWhile those two moves were major changes for the franchise, they might not be done yet.
Read more: Report: Celtics Miss Out on Top-Tier Offseason Target
According to a report from NBA insider Jake Fischer, Boston is still showing interest in two other potential trades this offseason.
"As we discussed, I think the Celtics are still very active in taking trade calls—maybe even making trade calls. There was some conversation last week between Memphis and Boston about something. We're still looking to track down more info on that. But rival teams are definitely still under the impression that Boston is looking for deals involving both Anfernee Simons and Georges Niang," Fischer said.
Simons is currently owed over $27.6 million in the final year of his contract. He could be moved to save more financially, but Stevens did speak out recently and talk about the 26-year-old's future and potential fit with the team.
"Anfernee is a guy people out here probably don't see as much because of the time that they play," Stevens said. "But his ability to score, to shoot the ball, make really hard shots, is pretty elite. And you look, a guy that's 26 years old and averaged 20 a game for three straight years."
Read more: Report: Lakers May Face Luka Doncic Threat From Western Conference Rival
As for Niang, he has just one year left on his contract as well worth $8.2 million.
Of course, no one truly knows what a team is going to do. The Celtics could very well head into the 2025-26 season with both Simons and Niang on the roster.
Expect to continue hearing rumors surrounding Boston. At the very least, the Celtics are a team worth keeping an eye on as a franchise potentially still open for business.
For more on the Boston Celtics and general NBA news, head on over to Newsweek Sports.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
What To Expect From Vertex Pharmaceuticals's (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here's what to look for. Vertex Pharmaceuticals missed analysts' revenue expectations by 2.3% last quarter, reporting revenues of $2.77 billion, up 3% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance slightly missing analysts' expectations. Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Vertex Pharmaceuticals's revenue to grow 9.8% year on year to $2.90 billion, improving from the 6.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street's revenue estimates three times over the last two years. Looking at Vertex Pharmaceuticals's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Vertex Pharmaceuticals's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $505.19 (compared to the current share price of $464). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Washington Post
43 minutes ago
- Washington Post
Red Sox pitcher Tanner Houck to undergo Tommy John surgery
BOSTON — Boston Red Sox right-hander Tanner Houck's attempt to come back this season is over. Manager Alex Cora said Saturday that Houck will undergo Tommy John surgery. An All-Star last season, the 29-year-old Houck went on the injured list in mid-May with a right flexor strain after going 0-3 with an 8.04 ERA in nine starts. 'Tanner's going to have Tommy John surgery,' Cora said before the Red Sox beat the Houston Astros 7-3 at Fenway Park. 'He went to see Dr. Meister there in Texas and that was the recommendation,' Cora said. 'We don't have a date yet, but he's going to have it.' Houck had a strong 2024 season, finishing seventh in the American League with a 3.12 ERA in 30 starts, but was only able to make five rehab appearances after going on the IL. 'Tough year for him, tough year for us,' Cora said of the season-ending news. 'But he'll kill the rehab, he'll do his job, and when he comes back, he's going to be OK.' Houck earned his first All-Star appearance by going 8-6 with a 2.54 ERA in the first half. He struggled after the break, going 1-4 with a 4.23 ERA. He worked an inning at the All-Star Game in Texas last year, giving up three hits including a homer to Shohei Ohtani. 'A year ago I was at the All-Star game and now this year, going under the knife again, unfortunately. It's just a mater of time of putting the pieces back together, coming back stronger and just getting back out there,' Houck said Sunday morning in Boston's clubhouse. 'I know the minimum (to return) is probably around the 12-month mark, 12-to-14 month mark. With that being said, if everything goes right, 12 months from now, I plan on being back out there, running out to the mound at Fenway.' He's the third Boston starting pitcher to suffer a season-ending injury. Hunter Dobbins tore the anterior cruciate ligament in his right knee covering first base last month and Kutter Crawford underwent right wrist surgery. The team hopes the pickup of righty Dustin May at the trade deadline from the Los Angeles Dodgers will bolster the staff. He's expected to make his first start for the Red Sox on Wednesday at Fenway. 'It was definitely a ride of emotions, up and down,' said May, sitting in the dugout on Saturday of being dealt to Boston. 'Sad leaving because I've been there my whole career, but very, very excited to be joining this organization.' May knew his days as a starter with the Dodgers were likely coming to an end this season with a few starters expected to come off the injured list. 'I was kid of pushed out,' he said. 'We've got quite a few guys there in that organization. I couldn't be more excited and thrilled to be here and be a part of it.' ___ AP MLB:
USA Today
2 hours ago
- USA Today
Damian Lillard hired to be Weber State men's basketball general manager
Damian Lillard is adding to his workload – outside the NBA. In front of fans during Weber State's Alumni Classic on Aug. 2, the nine-time NBA All-Star guard announced that he has agreed to return to his alma mater to serve as the general manager for the Wildcats' men's basketball program that he once starred in. "Success doesn't come overnight, especially in today's ever-changing basketball landscape. College athletics is constantly evolving, and building a strong program requires time, trust, and commitment. I believe in what this program represents and the culture that continues to grow at Weber State," Lillard said in a statement. "The support of our community is vital to the program's success, and I am committed to playing a greater role in that effort. This opportunity allows me to be even more involved in shaping the future of Weber State basketball." REQUIRED READING: Charlie Baker doubts NCAA basketball tournament expansion can happen for 2025-26 season Noted in Weber State's news release, Lillard will work with the men's basketball staff and Weber State's athletic department in his role. He is also the latest prominent NBA figure to take on a general manager role in college basketball. The two-time Big Sky Player of the Year joins Golden State Warriors guard Steph Curry and Atlanta Hawks guard Trae Young to do so at their alma mater, with Shaquille O'Neal taking on the role at Sacramento State. "I feel like I can do a lot to help the program be successful, to help the players even individually continue to grow their careers past college, that's something that I'm passionate about," Lillard told the Standard-Examiner. In his four seasons at Weber State from 2009-2012, Lillard averaged 18.8 points and 3.5 assists per game while shooting a career 44.6% from the field and 86.7% from beyond the arc. His standout senior season earned him All-America honors, making him the first Big Sky player to achieve that feat. He was drafted No. 6 overall by the Trail Blazers in the 2012 NBA Draft. "From his days as a Wildcat to his success as a professional, Damian Lillard has remained deeply connected to Weber State, leaving an enduring mark on our university," Weber State's Director of Athletics Tim Crompton said in a statement. "This new role allows him to contribute his vision and experience in a more formal way, further elevating our program. His support provides Coach Duft and the program a tremendous advantage as we continue building for the future. Damian's dedication to Weber State is stronger than ever, further cementing his lasting impact on our community." Lillard signed a three-year, $42 million contract with the Portland Trail Blazers on July 18 after the Milwaukee Bucks waived him. He is expected to miss the 2025-26 season with the Trail Blazers as he recovers from a torn Achilles tendon injury that he sustained during the first round of the NBA Playoffs with the Bucks.
